Dr. Jim Omel – The patient / cancer research advocate viewpoint from ASCO 2021
By Adam Barkay|2021-06-15T21:27:35+00:00June 15th, 2021|All, ASCO 2021|Comments Off on Dr. Jim Omel – The patient / cancer research advocate viewpoint from ASCO 2021
About the Author: Adam Barkay
Related Posts
Sept 7th 2023- Prof. Alvaro Urbano- Fractionated Initial Infusion and Booster Dose of ARI0002h, a Humanised, BCMA-Directed CAR T-cell Therapy, for Patients with Relapsed or Refractory Multiple Myeloma (CARTBCMA-HCB-01): a Single-Arm, Multicentre, Academic Pilot Study
Sept 7th 2023- Prof. Alvaro Urbano- Fractionated Initial Infusion and Booster Dose of ARI0002h, a Humanised, BCMA-Directed CAR T-cell Therapy, for Patients with Relapsed or Refractory Multiple Myeloma (CARTBCMA-HCB-01): a Single-Arm, Multicentre, Academic Pilot Study
Sept 5th 2023- Prof. Uwe Platzbecker- Recent Approval of Luspatercept as First-Line Treatment of Anemia in Adults with Lower-Risk MDS who May Require Transfusions
Sept 5th 2023- Prof. Uwe Platzbecker- Recent Approval of Luspatercept as First-Line Treatment of Anemia in Adults with Lower-Risk MDS who May Require Transfusions
Aug 28th 2023- Prof. Michael Jordan- HLH-like Toxicities Predict Poor Survival After the Use of Tisagenlecleucel in Children and Young Adults with B-ALL